The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.

Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.

SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.

A vaccine expert explains that such answers likely won’t come until a vaccine has already been approved and administered to millions of people.

An imaging agent reveals aggregated tau protein in the brain during PET scans and could improve the diagnosis of neurodegenerative diseases, particularly tauopathies.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Government leaders claim the reductions are necessary to free up assets to deal with COVID-19 and address corruption in research.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.